Esperion Therapeutics, Inc., founded in 2008, is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The company offers unique, life-saving solutions to combat the risk of cardiovascular disease, which remains the #1 killer of men and women worldwide. However, the company is not stopping there. Esperion is invested in its pioneering intellectual property to support the company into 2030 and beyond. Today’s Esperion is priming to become more than a cardiovascular company by exploring broad spectrum opportunities in categories with no current standard of care.
Esperion's team is working toward expansion into viable global markets while working toward its vision to become more than a cardiovascular company. The company is focused on its Next Gen Program to explore new therapeutic opportunities in ACLY biology, with the goal to develop next-generation inhibitors optimized to address multiple life-threatening diseases.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline.
Our Vision
Innovation Today, for Healthier Lives Tomorrow
Our Mission
At Esperion, we are working tirelessly to deliver innovative medicines that help patients reach their goals today, tomorrow, and into the future.
Our Quality Philosophy
Quality is in all we do because all we do is for our patients.
Esperion’s passion for quality is an integral part of our company culture and is embedded in every aspect of the organization. We are committed to applying the highest quality standards to develop and deliver safe, effective pharmaceutical products that significantly improve the quality of life for the patients and clinical trial participants we serve.